alexa Preventing Metastasis by Targeting Lymphatic Vessels with Photodynamic Therapy Based on Nanostructured Photosensitizers | OMICS International
ISSN: 2157-7439
Journal of Nanomedicine & Nanotechnology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Preventing Metastasis by Targeting Lymphatic Vessels with Photodynamic Therapy Based on Nanostructured Photosensitizers

Longo JPF1*, Muehlmann LA2, Almeida-Santos MFM1 and Azevedo RB1

1Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brazil

2Faculty of Ceilandia, University of Brasilia, Brazil

*Corresponding Author:
Longo JPF
Department of Genetics and Morphology
Institute of Biological Sciences
University of Brasília, Brazil
Tel: 55 61 3107-3087
E-mail: [email protected]

Received Date: June 27, 2015 Accepted Date: July 30, 2015 Published Date: October 01, 2015

Citation: Longo JPF, Muehlmann LA, Almeida-Santos MFM, Azevedo RB (2015) Preventing Metastasis by Targeting Lymphatic Vessels with Photodynamic Therapy Based on Nanostructured Photosensitizers. J Nanomed Nanotechnol 6:318. doi:10.4172/2157-7439.1000318

Copyright: © 2015 Longo JPF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nanomedicine & Nanotechnology

Since the description of the Enhanced Permeability and Retention (EPR) related to the pathophysiology of tumor tissue [1], thousands reports have been published showing an improvement in the therapeutic index of classical chemotherapeutic drugs with the use of nanoparticles. The EPR effect is a phenomenon based on the presence of aberrant immature, tortuous, hyper permeable blood vessels, and a low density, dilated, leaky and discontinuous lymphatic vessels within tumor tissue [2]. This specific condition produce a space where some types of circulating materials can go in due to the high permeable vasculature; however the way out is not that easy. The key point of this phenomenon is the size cut-off natures of aberrant, enlarged, and discontinuous endothelium produced in tumor blood vessels. While normal constitutive vessels have intercellular openings with 1-100 nm, tumor vessels have defective opening intercellular space with 400-500 nm. These size differences produce a high permeable tissue environment to nanometric materials, fact that explain the efficacy improvement of drug when entrapped in drug nano-carriers [2].

As described previously, one of the most attractive features of EPR is the possibility of passively increasing nanoparticles input into tumor tissues. However, some publications have highlighted the possibility that nanoparticles can achieve not only the blood vasculature, but also the tumor draining lymphatic vessels. Lymphangiogenesis has been associated with inflammation, cancer metastasis, autoimmunity, tolerance and transplant rejection, and thus, targeted lymphatic ablation is a potential therapeutic strategy for treating or preventing such events [3].

As described above tumor lymphatic vessels are produced as aberrant enlarged forms that work as open roads to sentinel regional lymph nodes, which may pave the way for metastasis spread to distant organs, such as lung and liver. It’s possible to use the EPR effect to reach these tumor-associated lymphatic vessels. In addition, an alternative choice to improve nanoparticle concentration within these structures is the intratumoral or peritumoral injection [4]. This strategy aims to place nanoparticles within the interstitial space, which are subsequently absorbed by draining lymphatic vessels due to a low pressure, a typical pattern of these vessels.

This approach was previous described [5] in an elegant experimental set-up. In that report, authors showed the specific ablation of tumor-associated lymphatic vessels, as well as destruction of in-transit metastatic tumor cells inside lymphatic vessels after peritumoral injection of photosensitizer (PS) associated to nanocarriers using Photodynamic Therapy (PDT). PDT is a combination of PS molecules and harmless light to produce an oxidative stress and cytotoxicity in the surrounding tissue where the PSs are accumulated [6]. Since lymphatic vessels passively accumulate the PS, PDT can be used as an innovative approach due to the specificity of the treatment. Noteworthy, this report showed that experimental animals presented significant reduction of distant metastasis when treated with this PDT protocol [5].

After this first publication describing the ablation of lymphatic vessels with PDT, we published two reports involving the prevention and reduction of metastasis with PDT and nanostructured photosensitizers in two different tumor models: (1) a mice tongue tumor [7], showing the prevention of loco-regional lymph node metastasis; and a mice breast cancer model [8], showing the prevention of lung metastasis after PDT application.

This lymphatic vessels ablation after PDT is strongly related to the basic mechanisms involved in PDT. Basically, PDT works due to three different biological mechanisms: (1) first the photochemical reaction acts directly against target cells, inducing a direct cytotoxic activity [9]; (2) second, PDT promotes the shutdown of surrounding blood and lymphatic vessels [10]; and (3) third, PDT stimulate immune system against tumor cells. It is worth to note that some authors [3] demonstrated that it is possible to establish PDT conditions to specifically destroy lymphatic vessels.

Thus, concerning the second mechanism, related to the antivascular therapy, we propose that PDT could be applied to destroy not only blood vessels structures, but also lymphatic tumor vessels,therefore preventing metastatic cell migration by this pathway. A scheme describing the general pathway of metastatic spread and the PDT prevention activity is presented in Figure 1. The idea described previously [5] and confirmed by our group [7,8] is that PDT can be used as vascular shutdown tool to destroy those cell migration pathways, preventing, at least partially the establishment of metastatic lesions. It is also important to call the attention that besides blood vessels shutdown PDT can also stimulate the immune system, making it a useful protocol to be applied in combination to other cancer therapy, in order to improve treatment outcomes and patient survival after the diagnosis with neoplastic lesions (Figure 1).

nanomedicine-nanotechnology-General-pathway-metastatic

Figure 1: General pathway of metastatic spread and the PDT prevention activity.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 12264
  • [From(publication date):
    October-2015 - Feb 18, 2018]
  • Breakdown by view type
  • HTML page views : 8411
  • PDF downloads : 3853
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version